Business Models and COGS Subcommittee

Charter

The Business Models and COGs Subcommittee strives to:

  • Map out the manufacturing process and COGs considerations as they relate to optimizing the Buisness Model, including reimbursement and adoption into standard of care, for both autologous and allogeneic cell therapy products.

Projects and Objectives

  • The Business Models and COGs Subcommittee will collect information from ISCT stakeholders via online surveys to assist in the development of educational webinars, white papers and roadmaps to support decision-making in cell therapy manufacturing.

 


 


 

Committee Chair


 

William Milligan
Chair
Steminent Biotherapeutics Inc.
Vancouver, BC, Canada

 

Committee Members

 

Allen Chen, PhD
ASTAR
Singapore

Suzanne Farid, PhD
University College London
London, England

John Fink, MSc
Brooks Life Science Systems
Chelmsford, MA, United States

Ian Fitzpatrick, MSc
Scinogy
Mount Waverley, Victoria, Australia

Yonatan Lipsitz
University of Toronto
Toronto, ON, Canada

Charles Mooney
Oklahoma Blood Institute
Oklahoma City, O, United States

Evelien Stalmeijer
eXmoor pharma concepts ltd
Berkshire, United Kingdom

Kah Yong Tan, PhD
ASTAR
Singapore
David Smith
PCT Cell Therapy Services
New York City, NY, United States
Colin Lee Novick
CJ Partners Inc
Tokyo, Japan
Allen Chen, PhD
ASTAR
Singapore

© 2017 International Society for Cellular Therapy. All rights reserved.
ISCT, International Society for Cellular Therapy, and the ISCT logo are registered service marks of The International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of The International Society for Cellular Therapy.